CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 24 enrolled
Drug / intervention
Furosemide 40 mg +1 moredrug
Likely dose
Furosemide 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04982874
NCT04982874N/ACompleted
CompareCT.gov

Bioequivalence Study of Furosemide in Indonesian Healthy Volunteers

PT. Kimia Farma (Persero) Tbk·interventional·Posted Jul 29, 2021·Updated Nov 2, 2023

In Brief

A clinical study evaluating Furosemide 40 mg and Lasix® 40 mg Tablet for Drug Use. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this research was to investigate whether Furosemide 40 mg tablet manufactured by PT. Kimia Farma Tbk was bioequivalent to its reference drug and Lasix® 40 mg Tablet manufactured by PT. Aventis Pharma, Indonesia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrug Use
CountriesIndonesia
CollaboratorsPT Pharma Metric Labs

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJul 29, 2021
Enrollment StartDec 13, 2019
Primary CompletionJan 17, 2020
Study CompletionJan 29, 2020
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 4.9 years ago

Interventions

Furosemide 40 mgdrug

Administered with 240 mL of water

Lasix® 40 mg Tabletdrug

Administered with 240 mL of water